{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:51:20Z","timestamp":1791906680709,"version":"4.3.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Germline genetic testing (GT) for hereditary cancer risk can inform cancer treatment, screening, and prevention, yet testing rates remain low. Alternative strategies are needed to improve facilitation of GT.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare 2 patient-level interventions to increase uptake of hereditary cancer GT against usual care.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The Michigan Genetic Hereditary Testing (MiGHT) randomized clinical trial analyzed self-reported GT outcome data from participants meeting clinical GT criteria between April 21, 2022, and November 21, 2025. Participants were adults (age \u226518 years) who met national criteria for genetic evaluation and had not previously completed germline GT recruited from oncology, primary care, and gastroenterology practices; research registries; and the general public in Michigan. Data were analyzed from April 30, 2025, to May 1, 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized to either telephone-based health coaching, a self-directed digital intervention, or usual care. Both interventions incorporated genetics education and motivational interviewing concepts.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n GT uptake was assessed at 6- and 12-month time points. The primary outcome was completion of GT by 6 months. The effects of study group on GT uptake were evaluated using logistic regression, adjusting for cancer history, age, gender, and race.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 793 participants (median [IQR] age, 64 [51-71] years; 458 [57.8%] female) were randomized to health coaching (261 participants), the digital intervention (265 participants), or usual care (267 participants). Overall, 31 participants (4.9%) reported completing GT by the 6-month time point, and 76 participants (9.6%) underwent GT across the 12-month study period. Compared with usual care, participants in the digital intervention group had higher odds of completing GT by 6 months (adjusted odds ratio [AOR], 3.88; 97.5% CI, 1.27-14.80), while those in the health coaching group had higher odds of completing GT by 12 months (AOR, 2.25; 97.5% CI, 1.11-4.77). Participants in the digital intervention group were more likely to express intention to test at 6 months (AOR, 2.36; 95% CI, 1.44-3.93), whereas those in the health coaching group had higher intention at both 6 (AOR, 2.99; 95% CI, 1.83-4.95) and 12 (AOR, 2.29; 95% CI 1.29-4.15) months compared with usual care.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of GT interventions, GT uptake was higher among participants who received the digital or health coaching interventions compared with usual care, although overall testing rates were low. These results underscore the importance of content delivery, motivational messaging, and alternative GT care models.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov ID:\n NCT05162846<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.38274","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:30:16Z","timestamp":1791905416000},"page":"e2638274","source":"Crossref","is-referenced-by-count":0,"title":["Digital and Coaching Interventions for Uptake of Cancer Genetic Testing"],"prefix":"10.1001","volume":"9","author":[{"given":"Sarah","family":"Austin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Delacroix","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"University of Michigan School of Social Work, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Koeppe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika N.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Arida-Moody","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Weiner","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Hawley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan, Ann Arbor"},{"name":"Ann Arbor Veterans Affairs Center for Clinic Management Research, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy R.","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Department of Human Genetics, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Health Behavior & Health Equity, University of Michigan School of Public Health, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Versha","family":"Pleasant","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina R.","family":"Ellis","sequence":"additional","affiliation":[{"name":"University of Michigan School of Social Work, Ann Arbor"},{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"},{"name":"Department of Health Behavior & Health Equity, University of Michigan School of Public Health, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Griggs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Department of Health Management and Policy, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Resnicow","sequence":"additional","affiliation":[{"name":"Division of Epidemiology & Community Health, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Stoffel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"zoi261029r2","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00553","article-title":"Prevalence and distribution of unexpected actionable germline pathogenic variants identified on broad-based multigene panel testing among patients with cancer.","volume":"8","author":"Landry","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"zoi261029r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1940-6207.CAPR-10-0345","article-title":"The search for unaffected individuals with Lynch syndrome: do the ends justify the means?","volume":"4","author":"Hampel","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"34","key":"zoi261029r4","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer.","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi261029r5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1586\/14737140.2015.1090879","article-title":"Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.","volume":"15","author":"Lerner-Ellis","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"zoi261029r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101765","article-title":"The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes.","volume":"43","author":"Aoun","year":"2022","journal-title":"Surg Oncol"},{"issue":"15","key":"zoi261029r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34375","article-title":"Effect of genetic profiling on surgical decisions at hereditary colorectal cancer syndromes.","volume":"10","author":"Goudarzi","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"zoi261029r8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10689-024-00367-2","article-title":"Cascade genetic testing: an underutilized pathway to equitable cancer care?","volume":"23","author":"Wilke","year":"2024","journal-title":"Fam Cancer"},{"issue":"4","key":"zoi261029r9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/DCR.0000000000002347","article-title":"Germline cancer risk profiles of patients with young-onset colorectal cancer: findings from a prospective universal germline testing and telegenetics program.","volume":"66","author":"You","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"zoi261029r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102702","article-title":"Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.","volume":"125","author":"Pensabene","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"zoi261029r11","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","article-title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.","volume":"33","author":"Jahn","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi261029r12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis.","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"key":"zoi261029r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100588","article-title":"Understanding the uptake and challenges of genetic testing guidelines for prostate cancer patients.","volume":"32","author":"Suri","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"zoi261029r14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95699","article-title":"Predictors of cancer genetic testing among U.S. adults: insights from the Health Information National Trends Survey 7.","volume":"17","author":"Roy","year":"2025","journal-title":"Cureus"},{"issue":"6","key":"zoi261029r15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.pec.2020.12.024","article-title":"Motivations and barriers to pursue cancer genomic testing: a systematic review.","volume":"104","author":"Smith-Uffen","year":"2021","journal-title":"Patient Educ Couns"},{"issue":"2","key":"zoi261029r16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cge.12868","article-title":"Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review.","volume":"92","author":"Willis","year":"2017","journal-title":"Clin Genet"},{"issue":"2","key":"zoi261029r17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s13187-020-01823-0","article-title":"Knowledge, attitudes, willingness to pay, and patient preferences about genetic testing and subsequent risk management for cancer prevention.","volume":"37","author":"Guo","year":"2022","journal-title":"J Cancer Educ"},{"issue":"1","key":"zoi261029r18","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1926","article-title":"Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing.","volume":"34","author":"Austin","year":"2025","journal-title":"J Genet Couns"},{"issue":"22","key":"zoi261029r19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/hmg\/ddaf139","article-title":"Breast cancer genetic testing uptake in the Midwest, USA: a systematic review of barriers and facilitators among minority populations.","volume":"34","author":"Meshram","year":"2025","journal-title":"Hum Mol Genet"},{"issue":"11","key":"zoi261029r20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/pros.24172","article-title":"Barriers and facilitators of germline genetic evaluation for prostate cancer.","volume":"81","author":"Loeb","year":"2021","journal-title":"Prostate"},{"issue":"5","key":"zoi261029r21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/jpm12050818","article-title":"Differences in willingness to undergo BRCA1\/2 testing and risk reducing surgery among the general public, cancer patients, and healthcare professionals: a large population-based survey.","volume":"12","author":"Chang","year":"2022","journal-title":"J Pers Med"},{"issue":"12","key":"zoi261029r22","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/cancers17121994","article-title":"Clinician recommendation for hereditary genetic testing in participants at increased risk for hereditary cancer.","volume":"17","author":"Delacroix","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5","key":"zoi261029r23","doi-asserted-by":"publisher","first-page":"E337","DOI":"10.1503\/cjs.008424","article-title":"Genetic literacy among surgeons who manage patients with cancer: a national survey of knowledge, perceptions, attitudes, and barriers.","volume":"68","author":"Fei","year":"2025","journal-title":"Can J Surg"},{"issue":"6","key":"zoi261029r24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41436-018-0349-1","article-title":"Disparities in genetic services utilization in a random sample of young breast cancer survivors.","volume":"21","author":"Nikolaidis","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"zoi261029r25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jgc4.1250","article-title":"Racial disparities in breast cancer hereditary risk assessment referrals.","volume":"29","author":"Peterson","year":"2020","journal-title":"J Genet Couns"},{"issue":"1","key":"zoi261029r26","doi-asserted-by":"publisher","DOI":"10.2196\/23523","article-title":"Barriers and facilitators to genetic service delivery models: scoping review.","volume":"10","author":"Raspa","year":"2021","journal-title":"Interact J Med Res"},{"key":"zoi261029r27","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.961128","article-title":"Barriers, interventions, and recommendations: improving the genetic testing landscape.","volume":"4","author":"Dusic","year":"2022","journal-title":"Front Digit Health"},{"issue":"1","key":"zoi261029r28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13063-023-07125-2","article-title":"The Michigan Genetic Hereditary Testing (MiGHT) study\u2019s innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial.","volume":"24","author":"Gerido","year":"2023","journal-title":"Trials"},{"issue":"22","key":"zoi261029r29","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"zoi261029r30","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines Insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024.","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"zoi261029r31","first-page":"1122","article-title":"NCCN Guidelines Insights: genetic\/familial high-risk assessment: colorectal, version 1.2021.","volume":"19","author":"Weiss","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"zoi261029r33","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.70122","article-title":"Psychosocial predictors of hereditary cancer genetic testing motivation in untested individuals.","volume":"34","author":"Austin","year":"2025","journal-title":"J Genet Couns"},{"issue":"5","key":"zoi261029r34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jgc4.1609","article-title":"Motivational interviewing for genetic counseling: a unified framework for persuasive and equipoise conversations.","volume":"31","author":"Resnicow","year":"2022","journal-title":"J Genet Couns"},{"issue":"4","key":"zoi261029r35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pec.2014.12.014","article-title":"Validation of the one pass measure for motivational interviewing competence.","volume":"98","author":"McMaster","year":"2015","journal-title":"Patient Educ Couns"},{"issue":"3","key":"zoi261029r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0185","article-title":"Strategies to assess risk for hereditary cancer in primary care clinics: a cluster randomized clinical trial.","volume":"8","author":"Swisher","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi261029r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32143","article-title":"Uptake of cancer genetic services for chatbot vs standard-of-care delivery models: the BRIDGE randomized clinical trial.","volume":"7","author":"Kaphingst","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi261029r1","volume-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2025"},{"key":"zoi261029r32","volume-title":"Cancer Detection and Diagnosis A Handbook of Emerging Technologies","author":"Austin","year":"2025"},{"key":"zoi261029r36","unstructured":"Michigan Department of Health and Human Services. About Michigan\u2019s Cancer Genomics Program. Updated June 23, 2022. Accessed September 9, 2026. https:\/\/www.michigan.gov\/mdhhs\/adult-child-serv\/childrenfamilies\/hereditary\/genomics\/brca\/about-michigans-cancer-genomics-program"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855266\/austin_2026_oi_261029_1791305192.73733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:30:18Z","timestamp":1791905418000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855266"}},"subtitle":["The MiGHT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.38274","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}